EGFR and non-small cell lung carcinoma: Despite advancements in treatments for metastatic non‐small cell lung cancer (NSCLC), patients harboring sensitizing epidermal growth factor receptor (EGFR) mutations ultimately experience treatment failure with frontline tyrosine kinase inhibitors (TKIs) [1, 2].